Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: CEO
Company: Fosun Kite Biotechnology Co., Ltd
个人简介:
Richard Wang, Ph. D and MBA, Chief Executive Officer, Fosun Kite Biotechnology Co. Ltd (a joint venture between Fosun Pharma and Kite Pharma), since March, 2017. Prior to joining Fosun Kite, Richard was a Chief Operation Officer for the Cellular Biomedicine Group (NASDAQ: CBMG). Richard led CBMG day-to-day operations and provided leadership and oversight to multiple functions (e.g., preclinical pharmacology, clinical development, manufacturing and technology (CMC), regulatory, quality assurance, project and administration), and was specifically responsible for the company’s stem cell technology platform and therapeutic business unit. He also supported the company’s immunotherapy pipeline (CAR-T and therapeutic vaccine) from the aspects of manufacturing, clinical development and registration strategy. Before that, Richard functioned as a site leader, senior director and head of operations for the GSK R&D Center in China, a director of strategic alliance, portfolio and operations for the AstraZeneca Innovation Center China, an associate director of discovery and early development project management in Bristol-Myers Squibb US, and a discovery group leader and senior scientist of the Procter & Gamble Pharmaceutical in the US, for more than 20 years with increasing leadership responsibilities in the therapeutic areas of oncology, neuroscience, muscular-skeletal and inflammatory diseases.
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: President/President & CEO
Company: SAPA China/Beijing Innocare Pharma Tech Co.,Ltd
个人简介:
Dr. Jasmine (Jisong) Cui is the co-founder, President & CEO of Beijing InnoCare Pharma Tech. Ltd. Dr. Cui is the expert of National Thousands Talents Plan and Beijing Specially Recruited Experts. InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. Prior to founding InnoCare, Dr. Cui was the General Manager of BioDuro (2011-2015). Her area of responsibility included BioDuro’s overall scientific and operational management, as well as business & resource management. Before BioDuro, Dr. Cui worked at Merck Research Laboratories for 14 years serving as Director of Cardiovascular Diseases where she provided project leadership for delivering 10 drug candidates. She also served as the Chair of Early Development Team for development of drug candidate from preclinical to clinical phase 2a for POC in humans. Additionally she headed the hypertension exploratory biomarker for identifying and developing preclinical and translatable biomarkers in cardiovascular diseases.Dr. Cui received her Ph.D. in biology from Purdue University and completed her postdoctoral fellowship at Howard Hughes Medical Institute affiliated with the University of Michigan. Dr. Cui was the 17th SAPA President with the honor to be the first female President in the history of SAPA. Currently, Dr. Cui is the president of SAPA China.
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: Board Chairman and CEO
Company: QIAGEN (Suzhou) Translational Medicine Co., Ltd
个人简介:
With 25 years of drug R&D experience and years of experience in translational science and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co., Ltd, which is an integrated precision medicine diagnostic solution provider for biomarker, companion diagnostics development and clinical testing. Nick was China GM and Corporate SVP for Frontage Lab, and a founding director and executive for Novartis China R&D center. Before that, Nick was a director at US OSI Pharmaceuticals and a manager at Pfizer global R&D center.  Nick filed 6 INDs/IMPD and 1 NDA/MAA for various dosage forms. Nick represented Pfizer serving on the PRQI working committee (formed among FDA, industry and academia) and also represented Bayhelix serving on sFDA CMC working committee. Before going to US, Nick worked and studied at Chinese Academy of Sciences. And he got his Ph.D. degree from University of Cincinnati. Nick is now a member of Bayhelix, a global association of Chinese Life Science Business Executives; an invited vice president of Jiangsu Life Science and Technology Association; and a director of Biomedical Committee (SEBMC), Sino-EU Chemical/Manufacturer Association. He is one of 5 founders and deputy director for China Precision Medicine and Companion Diagnostics Consortium. Nick is the recipient of the China Suzhou SIP Leading Talent Award, China Jiangsu Province Entrepreneur and Innovation Talent Award, and China national One-Thousand-Plan Talent Expert Award.
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: Head of R&D, Vice President
Company: I-Mab Biopharma Co., Ltd
个人简介:
Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co, Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 1-4. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds an academic position as the adjunctive professor in Indiana University School of Medicine.Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of  "Talent of Innovation" by the "National Thousand Talent Program". In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently Joan I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.